Photo by nci from unsplash
study. Blood. 2016;128(22):852. 13. Kantarjian HM, Silver RT, Komrokji RS, Mesa RA, Tacke R, Harrison CN. Ruxolitinib for myelofibrosis–an update of its clinical effects. Clin Lymphoma Myeloma Leuk. 2013;13(6):638–45. 14.… Click to show full abstract
study. Blood. 2016;128(22):852. 13. Kantarjian HM, Silver RT, Komrokji RS, Mesa RA, Tacke R, Harrison CN. Ruxolitinib for myelofibrosis–an update of its clinical effects. Clin Lymphoma Myeloma Leuk. 2013;13(6):638–45. 14. Vannucchi AM, te Boekhorst PAW, Harrison CN, He G, Caramella M, Niederwieser D, et al. EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis. Haematologica. 2019;104(5):947–54. 15. Griesshammer M, Vannucchi AM, le Coutre P, Tavares RS, Al-Ali HK, Raanani P, et al. Safety and efficacy of ruxolitinib in patients with low platelets enrolled in a phase 3b expanded-access study in myelofibrosis (MF). Blood. 2014;124(21):1859.
Journal Title: British Journal of Haematology
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!